The 5 Best Stocks to Buy for 2026

Nvidia and TSMC are highlighted as primary beneficiaries of accelerating AI-driven data-center demand, with TSMC reporting Q4 revenue up 26% year-over-year in USD and guiding to nearly 30% revenue growth in 2026 alongside planned capital spending of $52–$56 billion. Smaller AI infrastructure play Nebius projects a jump in annual run-rate from $551 million to $7–9 billion by year-end; non-AI names flagged as buy opportunities include The Trade Desk (down ~70% in 2025, but with analysts forecasting ~18% revenue growth this year and ~16% next, trading at ~17.5x forward earnings) and MercadoLibre (down ~20% with fintech-led growth potential across Latin America).

Analysis

Market structure: AI hardware winners (NVDA, TSM) capture outsized share as data-center spend front-loads; TSM’s $52–56B 2026 capex implies node-constrained supply and sustained pricing power for advanced wafers through 2026–2028, benefiting equipment makers and foundry-focused suppliers while depressing margin prospects for commodity CPU/legacy foundry vendors. Cloud AI renters (e.g., NBIS) benefit from GPU scarcity but face fragile unit economics if hardware supply normalizes or spot GPU pricing falls.

Risk assessment: Primary tail risks are geopolitical/export controls (Taiwan/China), a sudden capex pivot creating overcapacity by 2027, and execution/early-revenue-risk at NBIS. Time buckets: immediate (days) — sentiment remains skeptical so volatility likely; short-term (weeks–months) — earnings and TSM capex execution will reprice; long-term (to 2030) — secular AI demand could validate multiples but depends on TSM/NVDA capacity and memory pricing. Hidden dependencies include NVDA’s reliance on TSM node supply and NBIS’s dependence on leasing GPU inventory.

Trade implications: Implement concentrated long exposure to NVDA/TSM while avoiding or shorting execution-risk names like NBIS; use options to control drawdown — buy 9–18 month LEAP call spreads on NVDA/TSM and sell 3–6 month OTM put spreads on TTD to harvest elevated risk premia. Rotate modest weight into MELI as a 1–2% EM growth sleeve, increasing only if FX-adjusted GMV growth stays >20% YoY.

Contrarian angles: Consensus underestimates TSM pricing power and backlog — TSM is more of a structural buy than NVDA’s pure demand story implies; conversely NBIS’s leap to $7–9B ARR in months is likely overstated and a mean-reversion candidate. Watch for unintended consequences: aggressive fab buildouts can flip into a cyclical glut, compressing wafer prices and resetting multiples between 2027–2028.

Key Decisions for Investors

• Establish a 3% portfolio long in NVDA via staggered buys over 4–8 weeks; hedge by buying 12–18 month LEAP protective puts at ~25% OTM or use a 12–18 month call spread to cap cost (target hold through 2026 earnings cycle and reassess if NVDA guidance misses by >10%).
• Add a 3% long position in TSM, scale to 5% if shares fall another 15% while capex guidance ($52–56B) and advanced node utilization remain intact; consider 9–12 month calls if prefer option exposure to upside with limited capital.
• Initiate a small short or avoid long exposure to NBIS (size 1–2% portfolio risk); alternatively buy 6–9 month put spreads to express skepticism of the jump to $7–9B ARR and cap downside to defined loss.
• Sell 3–6 month cash‑secured puts on TTD at ~15% OTM (size equal to 1–2% notional) to collect premium given 17.5x forward earnings; if assigned, target a buy price implying >20% IRR over 18 months based on consensus revenue growth.
• Deploy 1–2% into MELI as a regional growth/differentiation hold; accumulate on FX-adjusted pullbacks where local-currency GMV growth remains >15% YoY or share price drops >20% from current levels.